Education: He graduated from Sun Yat-sen University, Doctor of Clinical Medicine

Outpatient time: Wednesday whole day (gynaecological tumor clinic in the morning, ovarian tumor clinic in the afternoon)

Medical specialty: standardized diagnosis and treatment of gynecological tumors and minimally invasive surgery.

He has been engaged in clinical research of obstetrics and gynecology for more than 20 years, and has rich clinical experience and exquisite surgical skills. He is especially good at minimally invasive and reproductive function preservation treatment for various gynecological malignant tumors. He is at domestic first-class level in treating the recurrence of ovarian cancer with surgery. His main research interest is the pathogenesis and integrated prevention and treatment of hereditary and recurrent platinum resistant ovarian cancer. He has presided over 11 general projects of National Natural Science Foundation of China, major innovation projects of Guangzhou, and Guangdong Provincial Natural Science Foundation. He has published more than 30 SCI-indexed papers.

Awards and Honors:

Outstanding Young Medical Talents of Guangdong Province in 2018

2021 Excellent Communist Party member of Guangdong Provincial People's Hospital

Professional memberships:

Member of the Minimally Invasive Tumor Free Defense Medicine Group of the Second Committee of the Minimally Invasive Medicine Professional Committee of the Chinese Medical Doctor Association

Vice Chairman of the First Committee of Gynecological Oncologist Branch of Guangdong Medical Doctor Association

Served as vice chairman of Cervical Cancer Prevention Committee of Guangdong Preventive Medical Association and other academic organizations

Academic achievements in recent five years:

1)Shao F(#), Duan Y(#), Zhao Y(#), Li Y, Liu J, Zhang C, He S*.PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. Aging (Albany NY), 2021,13(6):8975-8988.(Q1,IF=4.831)

2)Shen H(#), Liao B(#), Wan Z(#), Zhao Y, You Z, Liu J, Lan J, He S(#)*.PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer. Mol Ther Oncolytics,2021,20:499-507.(Q2,IF=4.115)

3)He S(#)*, Wang W(#), Wan Z(#), Shen H(#), Zhao Y, You Z, Liu J, Zhu L. FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway. Oncogenesis,2021,(1):6. doi: 10.1038/s41389-020-00301-y.(Q2,IF=6.119)

4)Huang Y(#), Chen X, You ZS, Gu F, Li L, Wang D, Liu J, Li Y, He S(*). The value of first-trimester platelet parameters in predicting gestational diabetes mellitus. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE,2020, 1-5. doi:10.1080/14767058.2020.1774543.(Q3,IF=1.737)

5)Chunyu Zhang(#), Yuandong Liao(#), Pan Liu(#), Qiqiao Du, Yanchun Liang, Shiyin Ooi, Shuhang Qin, Shanyang He(*), Shuzhong Yao(*), Wei Wang(*). FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism. Theranostics. 2020,10(15): 6561–6580.(Q1,IF=8.579)

6)Fengping Shao(#), Jun Liu, Yaoyun Duan, Li Li, Liqun Liu, Cai Zhang, Shanyang He(*). Efficacy and Safety of PARP Inhibitors as the Maintenance Therapy in Ovarian Cancer: A Meta-Analysis of Nine Randomized Controlled Trials. Bioscience Reports,2020,40(3):1-10.

7)Weiling He(#), Minzhi Hou(#), Hui Zhanmg(#),Shanyang He(#),Wenting Jiang(#), Chao Zeng, Xinlin Chen, Manman Xu, Cong Sun, Han Wang, Hongwei Shen, Yang Zhang, Jing Liu, Shijun Sun, Neng Jiang, Yongmei Cui, Yu Sun,Yangshan Chen, Jessica Cao, Chunlin Wang, Mengzhen Li, Yi Zhang, Liantang Wang, Jianhong Wang,Millicent Lin and Zunfu Ke.Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma.International Journal of Cancer, 2019, 144(6):1421-1431.

8)Jianhong Shang(#), Chen Yang(#), Hongwei Shen, Jun Liu, Shanyang He(*).Incidental finding of pre-peritoneal leiomyoma during laparoscopic hysterectomy: a case report and literature review.International Journal of Clinical and Experimental Medicine,2018, 11(3):2794-2798 .

9)Shanyang He(#)*, Yunhe Zhao(#), Xiaoping Wang, Yalan Deng, Zhiyong Wan, Shuzhong Yao and Hongwei Shen*.Up-regulation of long non-coding RNA SNHG20 promotes ovarian cancer progression via Wnt/β-catenin signaling.Bioscience Reports, 2018,38(1).

10)Shanyang He(#), Bing Liao(#), Yalan Deng, Chang Su, Jiuling Tuo, Jun Liu, Shuzhong Yao* and Lin Xu*.MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis. BMC Cancer,2017,17(1):673~684.(Q2,IF=2.933)

11)Shanyang He(#)*, Gang Niu(#), Jianhong Shang(#), Yalan Deng, Zhiyong Wan, Cai Zhang, Zeshan You and Hongwei Shen*.The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway. Journal of Experimental & Clinical Cancer Research,2017,36(1):137~148. (Q1, IF=5.646)

12)Shanyang He(#), Yalan Deng(#), Yanbin Liao, Xiaojin Li, Jun Liu and Shuzhong Yao.CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer., Oncology Letters, 2017,14(6):8156-8161.(Q4,IF=1.871)